Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
32 hedge funds and large institutions have $11.6M invested in Vincerx Pharma, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 3 closing their positions.
7% more capital invested
Capital invested by funds: $10.8M → $11.6M (+$798K)
4.01% less ownership
Funds ownership: 50.11% → 46.1% (-4%)
6% less funds holding
Funds holding: 34 → 32 (-2)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$41.5K |
| 2 |
Renaissance Technologies
New York
|
+$36.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$311K |
| 2 |
Goldman Sachs
New York
|
-$297K |
| 3 |
CC
Clearline Capital
New York
|
-$99.9K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$57.9K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$55K |
VINC Hedge Fund Activity: Q4 2023 in Review
32 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q4 2023, worth a combined $11.6M — up 7.4% from $10.8M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VINC and 1 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Marex Group, opening a new position worth an estimated $41.5K. The largest seller was Bank of America, cutting an estimated $311K.
- 32 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q4 2023, down from 34 in Q3 2023.
- Funds reported $11.6M of Vincerx Pharma, Inc. Common Stock stock for Q4 2023, up 7.4% quarter-over-quarter.
- 1 fund opened new Vincerx Pharma, Inc. Common Stock positions in Q4 2023 and 3 closed out, a net change of -2 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q4 2023 was Marex Group, an estimated $41.5K added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q4 2023 was Bank of America, an estimated $311K sold.
Based on aggregated 13F filings for Q4 2023.